» Articles » PMID: 36181003

Dexamethasone for the Treatment of Acute Respiratory Distress Syndrome: A Systematic Review and Meta-analysis

Overview
Specialty General Medicine
Date 2022 Oct 1
PMID 36181003
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This meta-analysis aimed to evaluate the efficacy and safety of dexamethasone in the treatment of acute respiratory distress syndrome (ARDS).

Methods: A systematic search of electronic databases was carried out from inception to May 1, 2022, including PUBMED, EMBASE, Cochrane Library, Wangfang, VIP, and CNKI. Other searches were also checked for dissertations/theses and the reference lists of the included studies. Two team members examined all citations and selected eligible articles. Randomized controlled trials (RCTs) reporting the efficacy and safety of dexamethasone for the treatment of ARDS were included, and the quality of eligible RCTs was assessed using the Cochrane Risk of Bias Tool. If necessary, we conducted data synthesis and meta-analysis. The primary outcome was all-cause mortality. Secondary outcomes were mechanical ventilation duration (day), ventilator-free status at 28 days; intensive care unit (ICU) free (day), ICU mortality, hospital mortality, sequential organ failure assessment (SOFA) as mean and range, SOFA as No. of patients, peak airway pressure (cmH2O), arterial oxygen pressure (mm Hg), days with PaO2 > 10kPa, PaO2, and the occurrence rate of adverse events.

Results: Four studies involving 702 patients were included in this analysis. This study showed that dexamethasone could significantly reduce all-cause mortality (odds ratio (OR) = 0.62, 95% confidence interval (CI) [0.44, 0.88], I2 = 30%, P < .001), and decrease ventilator-free status at 28 days (MD = 3.65, 95% CI [1.49, 5.80], I2 = 51%, P < .001). No significant differences in occurrence rates of adverse events were found between dexamethasone and routine or standard care.

Conclusions: Evidence from the meta-analysis suggests that dexamethasone is an effective and relatively safe treatment for all-cause mortality and ventilator-free status at 28 days in patients with ARDS. Owning to the small number of eligible RCTs, the conclusions of present study are warranted in the future study.

Citing Articles

Dexamethasone alleviates acute lung injury in a rat model with venovenous extracorporeal membrane oxygenation support.

Wei S, Du J, Zhai K, Yang J, Zhang R, Wu X BMJ Open Respir Res. 2024; 11(1.

PMID: 39632101 PMC: 11624713. DOI: 10.1136/bmjresp-2024-002394.


Green Tea Extract Reduced Lipopolysaccharide-Induced Inflammation in L2 Cells as Acute Respiratory Distress Syndrome Model Through Genes and Cytokine Pro-Inflammatory.

Priyandoko D, Widowati W, Lenny L, Novianti S, Revika R, Widya Kusuma H Avicenna J Med Biotechnol. 2024; 16(1):57-65.

PMID: 38605739 PMC: 11005400. DOI: 10.18502/ajmb.v16i1.14172.


Anti-Inflammatory Effects of Leaf on Lipopolysaccharide-Induced Acute Lung Injury.

Park J, Kim M, Choi Y, Kim Y, Lee S, Chung J Evid Based Complement Alternat Med. 2024; 2024:6653893.

PMID: 38230250 PMC: 10791263. DOI: 10.1155/2024/6653893.


Causal effects of gut microbiota on sepsis and sepsis-related death: insights from genome-wide Mendelian randomization, single-cell RNA, bulk RNA sequencing, and network pharmacology.

Yang S, Guo J, Kong Z, Deng M, Da J, Lin X J Transl Med. 2024; 22(1):10.

PMID: 38167131 PMC: 10763396. DOI: 10.1186/s12967-023-04835-8.